Haemophilia is a rare inherited bleeding disorder affecting the clotting cascade. It is also among the most expensive conditions managed in the SA private healthcare system — factor concentrate therapy can cost R200,000–R1,500,000 per year depending on severity, body weight, and product choice. As a CDL condition, medical aids are legally obligated to fund factor replacement therapy, but the financial architecture of haemophilia management requires specific understanding to navigate successfully.
What Is Haemophilia?
Haemophilia results from deficiency of a clotting factor. Two forms predominate:
- Haemophilia A: Factor VIII deficiency — approximately 80% of cases
- Haemophilia B: Factor IX deficiency — approximately 20% of cases
Severity is classified by residual clotting factor activity in the blood:
- Mild (>5% activity): Bleeding typically occurs only with significant trauma or surgery; spontaneous bleeds are uncommon
- Moderate (1–5% activity): Bleeding with minor trauma; occasional spontaneous joint or muscle bleeds
- Severe (<1% activity): Frequent spontaneous bleeds into joints (haemarthrosis), muscles, and soft tissue; significant risk of intracranial haemorrhage
Repeated haemarthroses cause progressive, irreversible joint damage — haemophilic arthropathy — particularly affecting knees, ankles, and elbows. In advanced cases, this results in chronic pain, reduced range of motion, and ultimately the need for orthopaedic joint replacement. Prevention of joint damage through adequate prophylaxis is the central goal of modern haemophilia management.
CDL Coverage: What the Scheme Must Fund
Haemophilia is a CDL condition under Regulation 8. Your scheme must fund factor concentrates as the CDL-minimum treatment standard. This is a legally protected, lifelong obligation — it cannot be capped by an annual rand limit, and it cannot be withheld based on age or disease duration.
However, the CDL obligation specifies a minimum treatment standard, not the most advanced treatment available. Coverage disputes most often arise around:
- Extended half-life (EHL) factor products: Require fewer injections per week; more convenient and associated with improved adherence. More expensive. Schemes may fund only standard half-life products under CDL minimum and require exceptional-needs authorisation for EHL.
- Emicizumab (Hemlibra): A subcutaneous bispecific antibody that mimics Factor VIII function. Revolutionised Haemophilia A management. Requires exceptional-needs authorisation from every scheme; cost is approximately R60,000/month.
- On-demand versus prophylaxis: The scheme must fund the standard of care for the severity level. For severe haemophilia, prophylaxis (preventive, scheduled factor infusions) is the standard of care — not on-demand treatment at time of bleed only.
Treatment Options Explained
On-demand factor replacement: Factor concentrate is infused at the time of a bleed. This was the historical standard and remains appropriate for mild haemophilia or specific situations. For severe disease, it allows accumulating joint damage that prophylaxis prevents.
Prophylactic factor replacement: Regular factor infusions — typically 2–3 times per week for standard half-life products — maintain factor levels above the spontaneous bleed threshold (~1% activity). This is the evidence-based standard of care for severe haemophilia and dramatically reduces joint bleeding, hospitalisation, and long-term arthropathy. Monthly cost for Factor VIII prophylaxis: approximately R30,000–R50,000 at standard half-life; R50,000–R70,000 for extended half-life products.
Emicizumab (Hemlibra): A subcutaneous antibody that bridges activated Factors IX and X, mimicking Factor VIII function without being an actual factor product. Used in Haemophilia A — with or without inhibitors. Administered subcutaneously once weekly, every two weeks, or once monthly. Monthly cost: approximately R55,000–R70,000. Requires exceptional-needs authorisation. Once approved, it is self-administered at home, significantly reducing the need for IV access and clinic visits, and is especially transformative for children and patients with poor venous access.
Inhibitors: The Most Serious Complication
Approximately 25–30% of patients with severe Haemophilia A, and a smaller proportion with Haemophilia B, develop inhibitors — antibodies against the infused factor concentrate that neutralise its effect. Inhibitor development renders standard factor replacement largely ineffective and requires treatment with bypass agents (activated prothrombin complex concentrate/aPCC, recombinant Factor VIIa) or emicizumab. These therapies are significantly more expensive. Annual treatment costs for severe haemophilia A with inhibitors on bypass agents can exceed R1,500,000.
Early inhibitor detection is critical. A haematologist will monitor for inhibitors through regular inhibitor titre testing (Bethesda assay). If inhibitors are identified, immediate escalation of the management plan and the funding application is required.
Haemophilia Treatment Centres
Haemophilia is a rare, complex condition best managed at a designated Haemophilia Treatment Centre (HTC) — a specialist centre with experienced haematologists, physiotherapists, and a multidisciplinary team. HTCs maintain emergency factor supplies, coordinate comprehensive care, and are equipped to manage surgical and inhibitor cases. Ask your scheme whether there is an HTC preference or requirement for optimal CDL benefit access.
Medication Cost Summary
All costs are estimates. SAHPRA SEP verification pending.
| Medication | Estimated Monthly Cost |
|---|---|
| Factor VIII concentrate (standard half-life prophylaxis) | R25,000–R45,000 |
| Factor VIII concentrate (extended half-life prophylaxis) | R45,000–R70,000 |
| Factor IX concentrate (standard half-life) | R15,000–R30,000 |
| Emicizumab (Hemlibra — Haemophilia A) | R55,000–R70,000 |
| Bypass agents (aPCC/rFVIIa — inhibitor patients) | R100,000–R200,000+ |
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Mild Haemophilia A/B — on-demand only | R50,000 – R150,000 |
| Moderate/severe — standard half-life prophylaxis | R200,000 – R500,000 |
| Severe HA on emicizumab prophylaxis | R600,000 – R900,000+ |
| Severe HA with inhibitors (bypass agents) | R800,000 – R1,500,000+ |
Gap Cover Relevance
Haemophilia is unusual: the primary cost driver is medication, not specialist consultation shortfalls. Factor concentrate and emicizumab costs are CDL-funded obligations. Gap cover is most relevant for haematologist consultation shortfalls and for orthopaedic joint replacement surgery in patients with advanced haemophilic arthropathy — total knee replacement or ankle arthroplasty, where specialist shortfalls can reach R40,000–R100,000. The gap OPL of approximately R220,000/year is adequate for these episodic orthopaedic events.
Plan Selection: Critical Questions
When selecting a plan with haemophilia:
- Are factor concentrates funded under CDL with no annual rand cap on the CDL benefit?
- Who is the designated factor concentrate supplier, and does it align with your haematologist's preferred product and your current prescription?
- Does the plan require treatment at a designated HTC, and is your treating haematologist affiliated with one?
- What is the exceptional-needs or non-formulary pathway for emicizumab or EHL products, and what documentation is required?
- How is perioperative factor concentrate (for surgery) authorised — under CDL or the in-hospital benefit?
Talk to Eldon
See which plans pay for haemophilia →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).